Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 18/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 17/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16844045 | 0.79 | CYP11B2 (0.49) | CYP11B2CYP11B1KCNJ1SLC22A12 | |
| SCHEMBL15786642 | 0.77 | CYP11B1 (0.57) | CYP11B2CYP11B1 | |
| SCHEMBL16844140 | 0.76 | PDE3B (0.43) | SLC22A12 | |
| SCHEMBL9612021 | 0.75 | CYP11B2 (0.68) | CYP11B2CYP11B1 | |
| SCHEMBL16841033 | 0.75 | CYP11B2 (0.40) | CYP11B2CYP11B1KCNJ1SLC22A12 | |
| SCHEMBL19656599 | 0.75 | CYP11B2 (0.47) | CYP11B2CYP11B1SLC22A12 | |
| SCHEMBL15605754 | 0.74 | CYP17A1 (0.40) | CYP11B2CYP11B1 | |
| SCHEMBL15588785 | 0.74 | TUBB4A (0.43) | CYP11B2CYP11B1 | |
| SCHEMBL16920518 | 0.73 | CYP11B2 (0.39) | CYP11B2CYP11B1KCNJ1SLC22A12 | |
| SCHEMBL19651370 | 0.73 | CYP11B2 (0.39) | CYP11B2CYP11B1KCNJ1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017194665-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2017-11-16 | — | — | WO | disclosed |
| US-9752075-B2 | Mesogenic media and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-09-05 | — | — | US | disclosed |
| US-20160298031-A1 | MESOGENIC MEDIA AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160289561-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-10-06 | — | — | US | disclosed |
| EP-2870217-B1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-20150203756-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | MERCK PATENT GMBH (DE) | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203756-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | CYP11B2 1424/4885CYP11B1 1497/4885KCNJ1 3369/4885 |
| US-20160289561-A1 | BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA | SP1, FOXM1, S100A11 | CYP11B2 1457/4885CYP11B1 1613/4885KCNJ1 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.